SCHEMBL3770400

SCHEMBL3770400

COc1ccc(C2(O)CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.54
ALDH1A1 P00352 3/20 0.54
TSHR P16473 1/20 0.54
KDM4E B2RXH2 1/20 0.46
ORAI1 Q96D31 1/20 0.46
ACHE P22303 1/20 0.46
SIGMAR1 Q99720 2/20 0.45
MEN1 O00255 2/20 0.44
LMNA P02545 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
POLB P06746 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
SLC6A1 P30531 1/20 0.43
SLC6A12 P48065 1/20 0.43
SLC6A11 P48066 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3765913 0.98 ALDH1A1 (0.57) KMT2AALDH1A1TSHRKDM4EORAI1
SCHEMBL3767778 0.88 LMNA (0.45) ALDH1A1KDM4ELMNASMN1; SMN2HTT
SCHEMBL3777229 0.88 KMT2A (0.60) KMT2AALDH1A1TSHRKDM4EMEN1
SCHEMBL3766299 0.86 HRH3 (0.54) KMT2AMEN1
SCHEMBL3767766 0.81 ACHE (0.68) KMT2AALDH1A1TSHRKDM4EORAI1
SCHEMBL13005925 0.81 KMT2A (0.57) KMT2AALDH1A1TSHRKDM4EACHE
SCHEMBL3777237 0.81 SMN1; SMN2 (0.64) KMT2AALDH1A1TSHRKDM4EORAI1
SCHEMBL3763175 0.81 GAA (0.60) KMT2AALDH1A1TSHRKDM4EACHE
SCHEMBL3772438 0.80 NPSR1 (0.44) KMT2AALDH1A1KDM4EMEN1SMN1; SMN2
SCHEMBL3762993 0.79 ALDH1A1 (0.60) KMT2AALDH1A1TSHRKDM4EACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KMT2A 242/4885ALDH1A1 1210/4885TSHR 436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.